Evidence map›Paper›PMID 38752685›Full record

ArticleCancer biology & medicine2024

Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer.

Xiuzhi Zhu, Xiaohan Ying, Yin Liu, Yunyi Wang, Li Chen, Zhiming Shao, Xi Jin, Yizhou Jiang, Zhonghua Wang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiuzhi Zhu *Key Laboratory of Breast Cancer in Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200000, China.
Xiaohan Ying *Key Laboratory of Breast Cancer in Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200000, China.
Yin LiuDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Yunyi WangKey Laboratory of Breast Cancer in Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200000, China.
Li ChenDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200000, China.
Zhiming ShaoKey Laboratory of Breast Cancer in Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200000, China.
Xi JinKey Laboratory of Breast Cancer in Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200000, China.
Yizhou JiangKey Laboratory of Breast Cancer in Shanghai, Shanghai Institute of Infectious Disease and Biosecurity, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200000, China.ORCID 0000-0003-3699-2630
Zhonghua WangDepartment of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200000, China.ORCID 0000-0003-3356-9319

Funding

National Natural Science Foundation of China 82103039Program of Shanghai Academic/Technology Research Leader 20XD1421100Wu Jieping Medical Foundation 320.6750.2021-10-64
6 · The paper itself

Abstract

objectiveTriple-negative breast cancer (TNBC) is a heterogeneous and aggressive cancer. Although our previous study classified primary TNBC into four subtypes, comprehensive longitudinal investigations are lacking.

methodsWe assembled a large-scale, real-world cohort comprised of 880 TNBC patients [465 early-stage TNBC (eTNBC) and 415 metastatic TNBC (mTNBC) patients] who were treated at Fudan University Shanghai Cancer Center. The longitudinal dynamics of TNBC subtypes during disease progression were elucidated in this patient cohort. Comprehensive analysis was performed to compare primary and metastatic lesions within specific TNBC subtypes.

resultsThe recurrence and metastasis rates within 3 years after initial diagnosis in the eTNBC cohort were 10.1% (47/465). The median overall survival (OS) in the mTNBC cohort was 27.2 months [95% confidence interval (CI), 24.4-30.2 months], which indicated a poor prognosis. The prognostic significance of the original molecular subtypes in both eTNBC and mTNBC patients was confirmed. Consistent molecular subtypes were maintained in 77.5% of the patients throughout disease progression with the mesenchymal-like (MES) subtype demonstrating a tendency for subtype transition and brain metastasis. Additionally, a precision treatment strategy based on the metastatic MES subtype of target lesions resulted in improved progression-free survival in the FUTURE trial.

conclusionsOur longitudinal study comprehensively revealed the clinical characteristics and survival of patients with the original TNBC subtypes and validated the consistency of most molecular subtypes throughout disease progression. However, we emphasize the major importance of repeat pathologic confirmation of the MES subtype.

Indexed as

Triple Negative Breast NeoplasmsAdultAgedBiomarkers, TumorChinaDisease ProgressionFemaleHumansLongitudinal StudiesMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPrognosisBiomarkers, Tumormetastasismolecular subtypeoverall survivalprimary tumorTriple-negative breast cancer

Identifiers

PMID38752685
PMCPMC11414218

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.